Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (1): 30-34.doi: 10.11958/20211215

• Monograph-Biliary Atresia and Liver Transplantation • Previous Articles     Next Articles

Research progress of adjuvant therapy after Kasai surgery for biliary atresia

GE Juntao1, 2, ZHAN Jianghua3△    

  1. 1 Graduate School, Tianjin Medical University, Tianjin 300070, China; 2 Department of Pediatric Surgery, the First Affiliated Hospital of Shandong First Medical University; 3 Department of General Surgery, Tianjin Children’s Hospital
  • Received:2021-05-24 Revised:2021-08-09 Published:2022-01-15 Online:2022-01-19
  • Contact: zhanjianghua E-mail:zhanjianghuatj@163.com

Abstract:

Abstract: Biliary atresia (BA) is a progressive disease involving both intrahepatic and extrahepatic bile ducts. Kasai portoenterostomy is the most widely used treatment strategy for BA. However, about 60% of the patients treated by Kasai operation have poor postoperative outcomes and still need liver transplantation in the future. Although the factors affecting the postoperative survival of children with BA are closely related to the BA classification, the surgical method (laparoscopic or traditional open), the age at the time of surgery, and liver lesions at the time of surgery, the adjuvant therapy after BA is still an area that can be improved to a great extent. In recent years, there have been many reports on postoperative BA, such as hormones, bile acid metabolism drugs, antibiotics and probiotics, etc. In this paper, the research progress of adjuvant therapy after BA is reviewed to further explore the prognostic value of adjuvant therapy in children with BA.

Key words: biliary atresia, portoenterostomy, hepatic, glucocorticoids, ursodeoxycholic acid, anti-bacterial agents, gastrointestinal microbiome, Kasai portoenterostomy, probiotics

CLC Number: